StockVS

Canopy Growth Corporation (CGC) Aandelenanalyse

Gezondheidszorg

Canopy Growth Corporation

$1.05

+$0.01 (+0.96%)

Laatst bijgewerkt: 26 mei 2026

Koersverloop

Analyse

Bedrijfsoverzicht

Canopy Growth Corporation is a leading entity engaged in the production, distribution, and sale of cannabis, hemp, and cannabis-related products across key international markets including Canada, Germany, and Australia. The company operates within the healthcare sector, specifically classified under the industry of drug manufacturers specializing in specialty and generic pharmaceuticals, which implies a focus on regulated therapeutic goods and distinct manufacturing capabilities. Its operational scale is defined by a market capitalization of $471.53M and an annual revenue of $278.39M, supported by an workforce of 960 employees. These valuation and revenue figures indicate that the company maintains a substantial presence in the specialized cannabis market, though the relatively modest market cap relative to its revenue suggests a valuation that is heavily influenced by sector-specific headwinds and profitability challenges rather than broad-based revenue expansion.

Financiële gezondheid

The company reported a revenue of $278.39M over the trailing twelve months, yet this generated a net income of $-327,294,016, revealing a significant disconnect where costs and expenses far exceeded total sales. This substantial gap between revenue and net income highlights a deeply challenged cost structure where operational expenditures, likely including regulatory compliance and manufacturing overhead, are consuming the entirety of top-line growth. The company's EBITDA stands at $-8,742,000, while free cash flow is negative at $-25,979,250, indicating a lack of financial flexibility to fund operations or capital expenditures without external financing. Margin analysis further underscores these structural pressures, with a gross margin of 26.6% suggesting moderate production efficiency, but an operating margin of -17.6% and a profit margin of -117.3% demonstrating severe underperformance in converting sales into operational profit. On the balance sheet, the company holds $371.48M in cash against $255.12M in debt, resulting in a debt-to-equity ratio of 33.65, which presents a leveraged position despite the significant cash buffer. Liquidity appears robust in the short term, evidenced by a current ratio of 5.34, meaning the company possesses more than five times the current assets needed to cover its current liabilities. However, the return on equity is -48.5% and the return on assets is -2.6%, metrics that collectively reveal that management has not yet been effective in generating positive returns on the capital invested by shareholders or utilized by the firm.

Waarderingsbeoordeling

Valuation metrics for Canopy Growth reflect its status as a loss-making enterprise, with a trailing P/E ratio that is N/A due to negative earnings and a forward P/E of -14.37. The negative forward P/E implies that the market is pricing in a long period of expected earnings contraction or significant restructuring costs before profitability can be restored. The price-to-book ratio stands at 0.71, indicating that the market values the company at less than its book value, which often suggests that investors perceive the assets as overvalued on a historical cost basis or that the business faces existential risks. Alternative valuation multiples such as the price-to-sales ratio of 1.69 and an EV/EBITDA of -32.08 suggest that the company is being valued primarily on its revenue generation potential rather than profitability, as the negative EV/EBITDA confirms the inability to generate earnings before interest, taxes, depreciation, and amortization. The stock's trading range over the last year spans from a 52-week low of $0.84 to a high of $2.38, providing a context for current price positioning relative to historical volatility. The beta of 2.32 indicates that the stock's price is highly volatile, moving with significantly greater magnitude than the broader market, which amplifies risk for investors during periods of sector uncertainty.

Growth & Income

Growth metrics show a revenue growth of -0.3% year-over-year and earnings growth that is N/A due to the lack of positive earnings in the trailing period. Since earnings are negative, it is impossible for them to grow faster than revenue in a traditional sense; rather, the company faces the challenge of reducing losses while maintaining revenue stability or growth. As a non-dividend payer, the company does not distribute a dividend yield, which is N/A, nor does it maintain a payout ratio of 0.0%, meaning the company retains all available cash flow rather than returning it to shareholders. This retention strategy implies that the company is reinvesting its limited resources into maintaining market share, regulatory compliance, or operational efficiency in hopes of turning the business around in the future. The overall growth and income profile for Canopy Growth Corporation is characterized by stagnant revenue, persistent losses, and a complete absence of dividend income, reflecting a high-risk investment scenario focused entirely on operational turnaround rather than shareholder returns.

Vergelijking met sectorgenoten

Canopy Growth Corporation (CGC) is actief in de Farmaceutische Fabrikanten - Specialistisch & Generiek-sector. Zo verhoudt het zich tot de naaste sectorgenoten op basis van marktkapitalisatie:

Bedrijf Ticker Marktkapitalisatie K/W-verhouding
Canopy Growth Corporation CGC $471.53M N/A
Takeda Pharmaceutical Company Limited TAK $50.14B 41.8
Haleon plc HLN $40.92B 18.5
Teva Pharmaceutical Industries Limited TEVA $40.30B 25.8

De gemiddelde K/W-verhouding in de Farmaceutische Fabrikanten - Specialistisch & Generiek-sector is 47.5x. Canopy Growth Corporation wordt verhandeld tegen een K/W van N/A.

Deze analyse is gegenereerd door AI en dient alleen ter informatie. Het vormt geen financieel advies. Gegevens kunnen vertraagd of onnauwkeurig zijn. Doe altijd je eigen onderzoek en raadpleeg een gekwalificeerde financieel adviseur voordat je beleggingsbeslissingen neemt.

Over Canopy Growth Corporation

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Bedrijfsbeschrijving wordt in het Engels weergegeven.

Bezoek website →

Belangrijke Cijfers

Marktkapitalisatie
$471.53M
K/W-verhouding
N/A
52-weken hoog
$2.38
52-weken laag
$0.84
Gem. Volume
10.13M
Bèta
2.39

Gegevens verstrekt door Yahoo Finance via yfinance. Dagelijks bijgewerkt.

Bedrijfsinfo

Beurs
NASDAQ
Land
Canada
Werknemers
960